|
|
|
|
| LEADER |
00000cam a22000007i 4500 |
| 001 |
SCIDIR_on1399251207 |
| 003 |
OCoLC |
| 005 |
20231120010754.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
230922s2023 mau o 000 0 eng d |
| 040 |
|
|
|a SFB
|b eng
|c SFB
|d YDX
|d EBLCP
|d GZM
|d OPELS
|d OCLCO
|
| 019 |
|
|
|a 1401052682
|a 1401057172
|
| 020 |
|
|
|z 9780443186677
|
| 020 |
|
|
|z 0443186677
|
| 020 |
|
|
|a 9780443186684
|q (electronic bk.)
|
| 020 |
|
|
|a 0443186685
|q (electronic bk.)
|
| 035 |
|
|
|a (OCoLC)1399251207
|z (OCoLC)1401052682
|z (OCoLC)1401057172
|
| 050 |
|
4 |
|a QP625.A27
|
| 082 |
0 |
4 |
|a 572.475
|
| 245 |
0 |
0 |
|a Adenosine A2A receptor antagonists /
|c Jiang-Fan Chen, Akihisa Mori
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press,
|c 2023.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a International review of neurobiology ;
|v v. 170
|
| 504 |
|
|
|a Includes bibliographical references
|
| 505 |
0 |
|
|a Front cover -- Series page -- Title page -- Copyright -- Contents -- Contributors -- Preface -- Chapter One: A2A adenosine receptor agonists, antagonists, inverse agonists and partial agonists -- 1 Introduction -- 2 A2AAR agonists -- 3 Positive allosteric enhancers (PAMs) -- 4 A2AAR antagonists and inverse agonists -- 5 Negative allosteric enhancers (NAMs) -- 6 A2AAR partial agonists -- 7 Conclusions -- References -- Chapter Two: Adenosine A2A receptor and glia -- 1 Preface -- 2 A2AR in astrocytes -- 3 Astrocyte A2AR and Alzheimer's disease -- 4 Astrocyte A2AR and PD -- 5 A2AR and microglia
|
| 505 |
8 |
|
|a 6 Microglial A2A receptor and process retraction -- 7 Microglial A2A receptor and neuroinflammation -- 8 Microglial A2AR and AD -- 9 Microglial adenosine A2AR and PD -- 10 Microglial adenosine A2A receptor and stroke -- 11 Microglial A2AR in other diseases -- 12 Role of other microglial adenosine A1 and A3 receptors -- 13 A2AR and oligodendrocytes -- 14 Perspective -- References -- Chapter Three: The adenosine A2A receptor in the basal ganglia: Expression, heteromerization, functional selectivity and signalling -- 1 Introduction -- 2 Expression of A2AR in the basal ganglia
|
| 505 |
8 |
|
|a 3 Functional selectivity and signalling of A2AR -- 3.1 A2ARs as monomers -- 3.2 A2ARs as heteromers -- 3.3 A2AR-containing heteromers with relevance in basal ganglia circuits -- 3.4 Multiple mechanisms of action of A2AR antagonists -- 3.5 A2AR mediates the adenosine-dopamine functional interactions in the basal ganglia -- 4 Heteromer expression in neurological diseases affecting the basal ganglia and in alterations of the reward circuits by drugs of abuse -- 5 Concluding remarks -- Conflict of interests -- Author contribution -- Funding -- References
|
| 505 |
8 |
|
|a Chapter Four: How and why the adenosine A2A receptor became a target for Parkinson's disease therapy -- How and why the adenosine A2A receptor became a target for Parkinson's disease therapy -- 1 Introduction -- 2 The relevance of the adenosinergic system and the A2A adenosine receptor -- 3 Adenosine A2A receptors and motor function -- 4 Adenosine A2A antagonists and dyskinesia -- 5 Adenosine A2A antagonists and motor function in Parkinson's disease -- 6 Other potential mechanisms of action of A2A adenosine antagonists -- 7 Adenosine antagonists and non-motor symptoms of Parkinson's disease
|
| 505 |
8 |
|
|a 8 Exploring the future potential of adenosine A2A antagonists in Parkinson's disease -- References -- Chapter Five: Adenosine A2A antagonists and Parkinson's diseaseAdenosine A2A antagonists and Parkinson's disease -- 1 Introduction -- 2 Receptor agonists -- 2.1 Dopamine receptor agonists -- 2.1.1 Ergot dopamine agonists -- 2.1.2 Non-ergot dopamine agonists -- 3 Inverse agonists -- 3.1 Serotonin receptor 2A inverse agonists -- 4 Receptor antagonists -- 4.1 Dopamine receptor antagonists -- 4.2 NMDA receptor antagonists -- 4.3 Acetylcholine receptor antagonists -- 4.4 Adenosine receptor antagonists
|
| 505 |
8 |
|
|a Chapter six -- Chapter seven -- Chapter eight -- Chapter nine -- Chapter ten -- Chapter eleven.
|
| 650 |
|
0 |
|a Adenosine
|x Antagonists
|x Therapeutic use.
|
| 650 |
|
0 |
|a Adenosine
|x Receptors.
|
| 650 |
|
0 |
|a Parkinson's disease
|x Treatment.
|
| 650 |
|
0 |
|a Neural receptors.
|
| 650 |
|
0 |
|a Neurobiology.
|
| 650 |
|
6 |
|a Ad�enosine
|0 (CaQQLa)201-0007623
|x Antagonistes
|0 (CaQQLa)201-0374866
|x Emploi en th�erapeutique.
|0 (CaQQLa)201-0373975
|
| 650 |
|
6 |
|a Ad�enosine
|0 (CaQQLa)201-0007623
|x R�ecepteurs.
|0 (CaQQLa)201-0375415
|
| 650 |
|
6 |
|a Maladie de Parkinson
|0 (CaQQLa)201-0016037
|x Traitement.
|0 (CaQQLa)201-0377521
|
| 650 |
|
6 |
|a Neuror�ecepteurs.
|0 (CaQQLa)201-0017003
|
| 650 |
|
6 |
|a Neurobiologie.
|0 (CaQQLa)201-0010246
|
| 655 |
|
0 |
|a Electronic books.
|
| 700 |
1 |
|
|a Chen, Jiang-Fan.
|
| 700 |
1 |
|
|a Mori, Akihisa.
|
| 776 |
0 |
8 |
|i ebook version :
|z 9780443186684
|
| 776 |
0 |
8 |
|c Original
|z 0443186677
|z 9780443186677
|w (OCoLC)1369510643
|
| 830 |
|
0 |
|a International review of neurobiology ;
|v v. 170.
|
| 856 |
4 |
0 |
|u https://sciencedirect.uam.elogim.com/science/bookseries/00747742/170
|z Texto completo
|
